Stu­art Peltz re­signs as PTC Ther­a­peu­tics CEO af­ter 25 years

Stu­art Peltz, the long­time CEO of PTC Ther­a­peu­tics who’s led the rare dis­ease drug de­vel­op­er since its found­ing 25 years ago, is step­ping down.

Suc­ceed­ing him in the top job is Matthew Klein, who joined PTC in 2019 and was pro­mot­ed to chief op­er­at­ing of­fi­cer in 2022. In a call with an­a­lysts, he said the CEO tran­si­tion has been planned for “quite some time” — in fact, as part of it, he gave the com­pa­ny’s pre­sen­ta­tion at the JP Mor­gan health­care con­fer­ence ear­li­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER